108 related articles for article (PubMed ID: 7569030)
1. The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects.
Van den Bogaert W; van der Schueren E; Horiot JC; De Vilhena M; Schraub S; Svoboda V; Arcangeli G; de Pauw M; Van Glabbeke M
Radiother Oncol; 1995 May; 35(2):91-9. PubMed ID: 7569030
[TBL] [Abstract][Full Text] [Related]
2. Concomitant cisplatin and radiotherapy in a conventional and modified fractionation schedule in locally advanced head and neck cancer: a randomised phase II EORTC trial.
Bartelink H; Van den Bogaert W; Horiot JC; Jager J; van Glabbeke M
Eur J Cancer; 2002 Mar; 38(5):667-73. PubMed ID: 11916549
[TBL] [Abstract][Full Text] [Related]
3. Late results of multiple fractions per day (MFD) with misonidazole in advanced cancer of the head and neck. A pilot study of the EORTC radiotherapy group.
Van den Bogaert W; van der Schueren E; Van Tongelen C; Horiot JC; Chaplain G; Arcangeli G; Gonzalez D; Svoboda V
Radiother Oncol; 1985 Feb; 3(2):139-44. PubMed ID: 3983422
[TBL] [Abstract][Full Text] [Related]
4. Early results of the EORTC randomized clinical trial on multiple fractions per day (MFD) and misonidazole in advanced head and neck cancer.
van den Bogaert W; van der Schueren E; Horiot JC; Chaplain G; Devilhena M; Raposo S; Leonor J; Schraub S; Chenal C; Barthelme E
Int J Radiat Oncol Biol Phys; 1986 Apr; 12(4):587-91. PubMed ID: 3516953
[TBL] [Abstract][Full Text] [Related]
5. The EORTC randomized trial on three fractions per day and misonidazole in advanced head and neck cancer: prognostic factors.
Van den Bogaert W; van der Schueren E; Horiot JC; De Vilhena M; Schraub S; Svoboda V; Arcangeli G; de Pauw M; van Glabbeke M
Radiother Oncol; 1995 May; 35(2):100-6. PubMed ID: 7569017
[TBL] [Abstract][Full Text] [Related]
6. The feasibility of high-dose multiple daily fractionation and its combination with anoxic cell sensitizers in the treatment of head and neck cancer. A pilot study of the Radiotherapy Group of the EORTC (European Organisation for Research on Treatment of Cancer).
Van den Bogaert W; van der Schueren E; Horiot JC; Chaplain G; Arcangeli G; Gonzalez D; Svoboda V
Int J Radiat Oncol Biol Phys; 1982 Oct; 8(10):1649-55. PubMed ID: 7153077
[TBL] [Abstract][Full Text] [Related]
7. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.
Fu KK; Clery M; Ang KK; Byhardt RW; Maor MH; Beitler JJ
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):589-97. PubMed ID: 7790243
[TBL] [Abstract][Full Text] [Related]
9. Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III-IV squamous cancers of the head and neck.
Fazekas J; Pajak TF; Wasserman T; Marcial V; Davis L; Kramer S; Rotman M; Stetz J
Int J Radiat Oncol Biol Phys; 1987 Aug; 13(8):1155-60. PubMed ID: 3301758
[TBL] [Abstract][Full Text] [Related]
10. Improved results with accelerated hyperfractionated radiotherapy of advanced head and neck cancer.
Leborgne F; Zubizarreta E; Fowler J; Ortega B; Mezzera J; Deus JL; Leborgne JH
Int J Cancer; 2000 Apr; 90(2):80-91. PubMed ID: 10814958
[TBL] [Abstract][Full Text] [Related]
11. Hyperfractionated radiotherapy with or without misonidazole: results of a prospective randomized study in stage III-IV squamous cell carcinoma of the head and neck.
Panis X; Nguyen TD; Froissart D; Demange L
Int J Radiat Oncol Biol Phys; 1984 Oct; 10(10):1845-9. PubMed ID: 6386760
[TBL] [Abstract][Full Text] [Related]
12. Radiation-free weekend rescued! Continuous accelerated irradiation of 7-days per week is equal to accelerated fractionation with concomitant boost of 7 fractions in 5-days per week: report on phase 3 clinical trial in head-and-neck cancer patients.
Skladowski K; Hutnik M; Wygoda A; Golen M; Pilecki B; Przeorek W; Rutkowski T; Lukaszczyk-Widel B; Heyda A; Suwinski R; Tarnawski R; Maciejewski B
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):741-6. PubMed ID: 22836063
[TBL] [Abstract][Full Text] [Related]
13. The use of misonidazole in association with a three-fractions per day regimen in advanced head and neck epidermoid cancer. A pilot study.
Awwad HK; Barsoum M; El Merzabani M; Omar S; El Badawy S; Ezzat S; El Baki HA; Zaki A
Am J Clin Oncol; 1983 Feb; 6(1):91-7. PubMed ID: 6301258
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy by multiple fractions per day (MFD) in head and neck cancer: acute reactions of skin and mucosa.
Van der Schueren E; Van den Bogaert W; Vanuytsel L; Van Limbergen E
Int J Radiat Oncol Biol Phys; 1990 Aug; 19(2):301-11. PubMed ID: 2394609
[TBL] [Abstract][Full Text] [Related]
15. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003.
Fu KK; Pajak TF; Trotti A; Jones CU; Spencer SA; Phillips TL; Garden AS; Ridge JA; Cooper JS; Ang KK
Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):7-16. PubMed ID: 10924966
[TBL] [Abstract][Full Text] [Related]
16. Randomized clinical trial on 7-day-continuous accelerated irradiation (CAIR) of head and neck cancer - report on 3-year tumour control and normal tissue toxicity.
Skladowski K; Maciejewski B; Golen M; Pilecki B; Przeorek W; Tarnawski R
Radiother Oncol; 2000 May; 55(2):101-10. PubMed ID: 10799721
[TBL] [Abstract][Full Text] [Related]
17. Concomitant boost radiotherapy compared with conventional radiotherapy in squamous cell carcinoma of the head and neck--a phase III trial from a single institution in India.
Ghoshal S; Goda JS; Mallick I; Kehwar TS; Sharma SC
Clin Oncol (R Coll Radiol); 2008 Apr; 20(3):212-20. PubMed ID: 18343310
[TBL] [Abstract][Full Text] [Related]
18. Radical irradiation and misonidazole in the treatment of T2 grade III and T3 bladder cancer.
Abratt RP; Sealy R; Tucker RD; Williams MA; Barnes DR; Johnson MB; Green JA; Cridland JS
Int J Radiat Oncol Biol Phys; 1983 May; 9(5):629-32. PubMed ID: 6853264
[TBL] [Abstract][Full Text] [Related]
19. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck.
Merlano M; Benasso M; Corvò R; Rosso R; Vitale V; Blengio F; Numico G; Margarino G; Bonelli L; Santi L
J Natl Cancer Inst; 1996 May; 88(9):583-9. PubMed ID: 8609658
[TBL] [Abstract][Full Text] [Related]
20. Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial.
Overgaard J; Mohanti BK; Begum N; Ali R; Agarwal JP; Kuddu M; Bhasker S; Tatsuzaki H; Grau C
Lancet Oncol; 2010 Jun; 11(6):553-60. PubMed ID: 20382075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
